secwatch.observer — SEC 8-K summary
======================================

Issuer:     Gain Therapeutics, Inc. (GANX)
CIK:        0001819411
Form:       8-K
Filed at:   2025-11-12T23:59:59+00:00
Accession:  0001104659-25-110343
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud

Gain Therapeutics Reports Q3 2025 Results and Phase 1b Data for GT-02287 in Parkinson's Disease
--------------------------------------------------------------------------------

- Completed enrollment of 21 participants in Phase 1b study of GT-02287, surpassing original target of 15.
- Initial data from first nine participants showed improvement in MDS-UPDRS scores, suggesting disease-slowing effect.
- Received Australian approval to extend Phase 1b dosing to 12 months; ~80% of participants joined extension.
- Net loss for Q3 2025 was $0.15 per share; cash and cash equivalents $8.8 million as of September 30, 2025.
- R&D expenses increased to $2.8 million from $2.6 million year-over-year, driven by Phase 1b trial costs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819411/000110465925110343/0001104659-25-110343-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819411/000110465925110343/ganx-20251112x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-110343

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer